LEXINGTON, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, ...
– Trial Includes Ethanol Interaction Assessments to Evaluate Participants’ Response to Alcohol After Receiving DCR-AUD – LEXINGTON, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ...
Dicerna intends to discover, develop, and commercialize novel therapies either on its own or in collaboration with pharmaceutical partners. Dicerna has strategic collaborations with Roche, Eli Lilly ...
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At ...
WATERTOWN, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Dicerna), a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi therapeutics, today celebrates the opening of a new 37,000 square-foot office and ...
We have been pretty impressed with the performance at Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) recently and CEO Douglas Fambrough deserves a mention for their role in it. Shareholders will have ...
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and ...
Danish drugmaker Novo Nordisk A/S (NYSE: NVO) has agreed to acquire US-based biotech Dicerna Pharmaceuticals Inc (Nasdaq: DRNA) in a $3.3 billion cash deal. Under the terms of the agreement announced ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) announced positive top-line results from the PHYOX2 pivotal clinical trial ...
Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Datadog, Home Depot and Walmart, on Friday. Denmark's Novo Nordisk to buy Dicerna ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results